Abnormalities of arachidonic acid metabolism are implicated in spasm and thrombosis in coronary arteries. Therefore, arachidonic acid metabolites were examined in patients with acute myocardial infarction (AMI). Plasma levels of thromboxane B2 (TXB 2), 6-keto prostaglandin F1α (6KPGF1α), leukotriene B4 (LTB4), and slow reacting substance of anaphylaxis (SRS-A) composed of leukotriene C4 (LTC4), leukotriene D4 (LTD4) and leukotriene E4 (LTE4), were measured in 19 AMI patients. Plasma levels of TXB2, LTB4, and SRS-A in systemic artery blood were significantly elevated during the acute stage (within twenty-four hours after the onset of chest pain) of AMI (TXB2, 0.36 ng/mL; LTB4, 0.75 ng/mL; and SRS-A [LTC4+LTD4+LTE 4], 0.96 ng/mL) compared with those of normal controls (TXB2, 0.18 ng/mL; LTB4, 0.44 ng/mL; and SRS-A [LTC4+LTD4+LTE 4], 0.31 ng/mL). These values decreased to near-normal control levels by one month after the AMI attack. The findings in this study suggest that abnormalities of arachidonic acid metabolism accompany, and may play a role in the pathogenesis of, AMI.
Get full access to this article
View all access options for this article.
References
1.
Henriksson P. , Wennmalm A., Edhag O., et al: In vivo production of prostacyclin and thromboxane in patients with acute myocardial infarction . Br Heart J55:543-548, 1986.
2.
Kurita A., Takase B., Uehata A., et al: Effect of a low dose of nisoldipine on the systemic and coronary hemodynamics and the prostaglandin metabolism of ischemic heart disease patients . Jpn Heart J31:287-297, 1990.
3.
Carry M., Korley V., Willerson JT, et al: Increased urinary leukotrienes excretion in patients with cardiac ischemia. Circulation85:230-236, 1992.
4.
Servi S., Ricevuti G., Mazzone A., et al: Granulocyte function in coronary artery disease. Am J Cardiol68:64B-68B, 1991.
5.
Friedrich T. , Lichey J., Niigam S., et al: Follow-up of prostaglandin plasma levels after acute myocardial infarction. Am Heart J109:218-222, 1985.
6.
Tada M., Hoshoda S., Kuzuya T., et al:Augmented thromboxane A2 generation and efficacy of its blockade in acute myocardial infarction. Int J Cardiol8:301-312, 1985.
7.
Takatsu Y., Yui Y., Hattori R., et al:Platelet aggregation and thromboxane B2 release in patients with acute myocardial infarction; their relation to coronary patency. Jpn Circ J52:314-320, 1988.
8.
Ezura D., Boyd LM, Goldstein RF, et al: Effects of calcium entry blockers on coronary constriction and myocardial constriction and myocardial ischemia due to leukotriene D 4. J Pharmacol Exp Ther233:229-234, 1984.
9.
Tomoike H., Egashira K., Yamada A., et al:Leukotriene C4- and D4-induced diffuse peripheral constriction of swine coronary artery accompanied by ST elevation on the electrocardiogram; angiographic analysis. Circulation75:480-487, 1987.
10.
Steven JF: Cooperative synthesis of leukotrienes by leukocytes and vascular cells . Ann NY Acad Sci524: 122-132, 1988.
11.
Simmet TH, Lange K., Degitz K., et al: Release and effects of sulfidopeptide-leukotrienes in heart and vascular tissues. Adv Prostaglandin Thromboxane Leukotriene Res16:261-267, 1986.
12.
Wittmann G. , Weinerowski P., Simmet TH, et al: Effect of muscarinic receptor stimulation on release of cysteinyl-leukotrienes and thromboxane B2 from anaphylaxtic guinea-pig hearts. Naunyn-Schmiedeberg Arch Pharmacol338:577-581, 1988.
13.
Isfc/Who: Nomenclature and criteria for diagnosis of ischemic heart disease. Circulation59:607-609, 1979.
14.
Kawano K., Sugita M., Oka M., et al: A simple, rapid and simultaneous extraction of thromboxane B2, 6-keto-prostaglandin F1α and prostaglandin E2. Jpn J Inflammation7:511-515, 1987 (in Japanese).
15.
Isono T., Koshihara Y., Murota S., et al: Measurement of immunoreactive-leukotriene C4 in blood of asthmatic children. Biochem Biophys Res Commun130:486-492, 1985.
16.
Katsura K., Minamizawa H., Katayama Y., et al: Plasma levels of leukotriene C4, B4 and slow reacting substance of anaphylaxis in chronological phases of cerebrovascular disease. Prostaglandin36:655-665, 1988.
17.
Passamani E. , Hoges M., Herman M., et al: The thrombolysis in myocardial infarction (TIMI) phase II pilot study: Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. J Am Coll Cardiol10:51B-64B, 1987.
18.
Wagner GS, Preye CJ, Palmeri ST, et al: Evaluation of a QRS scoring system for estimating myocardial infarction size: Specificity and observer agreement. Circulation65:342-347, 1982.
19.
Takase B.: Response of plasma eicosanoids and hemodynamics to myocardial ischemia and the salutary effect of calcium entry blocker. J Nippon Medical School57:4-54, 1990 (in Japanese).
20.
Romson JL, Hook BG, Kunkel SL, et al: Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation67:1016-1023, 1983.
21.
Hutton RA, Chow Fpr: Radioimmunoassay of 6-keto-PGF1α in plasma: An artifact introduced by plasma extraction. Br J Haematol51:327-332, 1982.
22.
FitzGerald GA, Brash AR, Falardeau P., et al: Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest68:1272-1276, 1981.
Hirsh PD, Hillis D., Cambell WB, et al: Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med304:685-691, 1981.
25.
Tada M., Hoshida S., Kuzuya T.: Augmented platelet reactivity and thromboxane A2 production: Possible aggravating factors in unstable angina. Jpn Circ J50: 181-187, 1986.
26.
Mullane KM, Read N., Salmon JA, et al: Role of leukocytes in acute myocardial infarction in anesthetized dogs: Relationship to myocardial inflammatory drugs. J Pharmacol Exp Ther228:510-522, 1983.
27.
Bajaj AK, Cobb MA, Virmani R., et al: Limitation of myocardial reperfusion injury by intravenous perfluorocheminal. Role of neutrophil activation. Circulation79:654-656, 1989.
28.
Litt MR, Jeremy RW, Weisman HF, et al: Neutrophil depletion limited to reperfusion reduces myocardial infarction size after 90 minutes of ischemia. Evidence for neutrophil mediated reperfusion injury. Circulation80:1816-1827, 1989.
29.
Mehta J., Dinerman J., Mehta P., et al: Neutrophil function in ischemic heart disease. Circulation79:549-556, 1989.
30.
Kuzuya T., Hoshida S., Nishida M., et al: Increased production of arachidonate metabolism in an occlusion-perfusion model of canine myocardial infarction. Circ Res21:551-558, 1987.
31.
Rosolowsky M., Falck JR, Willerson JT, et al: Synthesis of lipoxygenase and epoxygenase products of arachidonic acid by normal and stenosed canine coronary arteries . Circ Res66:608-621, 1990.
32.
Barst S., Mullane K.: The release of a leukotriene D4-like substance following myocardial infarction in rabbits. Eur J Pharmacol114:383-387, 1985.
33.
Chiu PS, Vemulapalli S., Bryant RW: Augmentation of leukotriene C4 and D4 release due to severe stenosis in the canine coronary artery stimulated by the calcium ionophore A23187. Biochem Pharmacol35:3593-3599, 1986 .
34.
Manfred K., Schonfeld W., Knoller J., et al: The metabolism of leukotrienes in blood plasma studied by high performance liquid chromatography. Biochem Biophys Acta833:135-143, 1985.
35.
Wagai F., Uetsuka N., Kinoshita M., et al: Inactivation of vasoactive substances in the canine lung. Jpn J Thorac Dis23:1337-1342, 1985 .
36.
Davi G., Traina M., Candela B., et al: Plasma 6-keto-PGF1α in acute myocardial infarction . Prostaglandins Leukotrienes and Medicine11:417-418, 1983.
37.
Ribeiro LT, Brandon TA, Hopkins DG, et al: Prostacyclin in experimental myocardial ischemia: Effects on hemodynamics, regional myocardial blood flow, infarct size and mortality. Am J Cardiol47:835-840, 1981.
38.
Tada M., Esumi K., Yamagishi M., et al: Reduction of prostacyclin synthesis as a possible cause of transient flow reduction in a partially constricted canine coronary artery. J Mol Cell Cardiol16:1137-1149, 1984 .
39.
Armstrong PW , Langevin LM, Watts DG: Randomized trial of prostacyclin infusion in acute myocardial infarction. Am J Cardiol61:455-457, 1988.
40.
Yui Y., Aoyama T., Murohara R., et al: Serum PGI2-regulating factors in acute myocardial infarction. Jpn Circ J51:462-464, 1987.
41.
Kurita A., Takase B., Uehata A., et al: The role of prostacyclin during exercise in paticnts with chronic angina pectoris. Jpn Heart J29:401-413, 1988.
42.
Mullane K., Hatala MA, Kraemer R., et al: Myocardial salvage induced by REV-5901, an inhibitor and antagonist of the leukotrienes. J Cardiovasc Pharmacol10:398-405, 1988.
43.
Itoh T., Toki Y., Hieda N., et al: Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C 4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart. Jpn Circ J53:1115-1121, 1989.
44.
Burr ML, Fehily AM, Gilbert JF, et al: Effects of changes in fat, fish, and fiber intakes on death and myocardial reinfarction; diet and reinfarction trial (DART). Lancet30:757-761, 1989.
